Published in J Immunol on November 15, 2008
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature (2010) 5.16
Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol (2010) 3.69
Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39
Prediction and pathogenesis in type 1 diabetes. Immunity (2010) 2.26
Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes (2009) 1.88
The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A (2008) 1.85
Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol (2009) 1.79
Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol (2010) 1.78
CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. J Immunol (2011) 1.76
Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127(low) regulatory T cells. Arthritis Rheum (2013) 1.71
Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum (2013) 1.70
Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care (2012) 1.52
Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. Diabetes (2009) 1.48
Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes (2011) 1.39
Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev (2014) 1.38
Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol (2012) 1.31
Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol (2010) 1.22
Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLoS One (2009) 1.16
T cells out of control--impaired immune regulation in the inflamed joint. Nat Rev Rheumatol (2013) 1.14
Translational mini-review series on Th17 cells: CD4 T helper cells: functional plasticity and differential sensitivity to regulatory T cell-mediated regulation. Clin Exp Immunol (2009) 1.04
Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis. Immunity (2010) 1.03
A cluster of coregulated genes determines TGF-beta-induced regulatory T-cell (Treg) dysfunction in NOD mice. Proc Natl Acad Sci U S A (2011) 1.03
Interindividual variation in human T regulatory cells. Proc Natl Acad Sci U S A (2014) 1.01
Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb Perspect Med (2012) 1.00
Low-dose antigen promotes induction of FOXP3 in human CD4+ T cells. J Immunol (2011) 0.96
Human regulatory T cells in autoimmune diseases. Curr Opin Immunol (2010) 0.95
The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res (2013) 0.94
Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care (2011) 0.93
T cell-driven initiation and propagation of autoimmune diabetes. Curr Opin Immunol (2011) 0.92
CD4⁺ CD45RA⁻ FoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin Exp Immunol (2013) 0.90
The dual effects of B cell depletion on antigen-specific T cells in BDC2.5NOD mice. J Immunol (2012) 0.89
Dendritic cell-targeted pancreatic beta-cell antigen leads to conversion of self-reactive CD4(+) T cells into regulatory T cells and promotes immunotolerance in NOD mice. Rev Diabet Stud (2010) 0.89
Homeostasis and function of regulatory T cells (Tregs) in vivo: lessons from TCR-transgenic Tregs. Immunol Rev (2014) 0.89
Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance. J Allergy Clin Immunol (2013) 0.88
Uncoupling of proliferation and cytokines from suppression within the CD4+CD25+Foxp3+ T-cell compartment in the 1st year of human type 1 diabetes. Diabetes (2011) 0.86
CD4 T cell differentiation in type 1 diabetes. Clin Exp Immunol (2015) 0.86
Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus. Int J Mol Sci (2015) 0.86
Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol (2015) 0.85
The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer. Adv Exp Med Biol (2009) 0.85
New technologies for autoimmune disease monitoring. Curr Opin Endocrinol Diabetes Obes (2010) 0.85
Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development. PLoS One (2014) 0.85
Inducing and Administering Tregs to Treat Human Disease. Front Immunol (2016) 0.84
Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus. Clin Exp Immunol (2013) 0.84
Mechanistic basis of immunotherapies for type 1 diabetes mellitus. Transl Res (2013) 0.84
Immune tolerance induction by integrating innate and adaptive immune regulators. Cell Transplant (2009) 0.84
Anti-cytokine therapies in T1D: Concepts and strategies. Clin Immunol (2013) 0.84
Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes. J Mol Cell Biol (2011) 0.84
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression. Front Immunol (2016) 0.83
Challenges in the pursuit of immune tolerance. Immunol Rev (2011) 0.83
Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. Biol Blood Marrow Transplant (2013) 0.83
Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol (2015) 0.83
Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases. Front Immunol (2015) 0.83
Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: implications for future use in cross-sectional assessment. PLoS One (2013) 0.82
Apoptosis of purified CD4+ T cell subsets is dominated by cytokine deprivation and absence of other cells in new onset diabetic NOD mice. PLoS One (2010) 0.81
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci Transl Med (2016) 0.81
Can we vaccinate against Type 1 diabetes? F1000 Biol Rep (2012) 0.81
Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology. Semin Immunopathol (2010) 0.80
Effector and naturally occurring regulatory T cells display no abnormalities in activation induced cell death in NOD mice. PLoS One (2011) 0.80
1,25-Dihydroxyvitamin D3 and its analog TX527 promote a stable regulatory T cell phenotype in T cells from type 1 diabetes patients. PLoS One (2014) 0.80
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis. Clin Immunol (2013) 0.80
Cutting edge: Genetic variation in TLR1 is associated with Pam3CSK4-induced effector T cell resistance to regulatory T cell suppression. J Immunol (2014) 0.80
Immune interventions to preserve β cell function in type 1 diabetes. J Investig Med (2016) 0.80
Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes. Clin Exp Immunol (2013) 0.79
Ganglioside GM1 deficiency in effector T cells from NOD mice induces resistance to regulatory T-cell suppression. Diabetes (2011) 0.79
Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes. Diabetes (2015) 0.79
Foxp3+ Treg expanded from patients with established diabetes reduce Helios expression while retaining normal function compared to healthy individuals. PLoS One (2013) 0.79
Etiopathogenesis of insulin autoimmunity. Anat Res Int (2012) 0.79
Low expression of CD39(+) /CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic children in contrast to high expression of CD101(+) /CD129(+) on Treg cells in children with coeliac disease. Clin Exp Immunol (2015) 0.78
CD8(+) T cells in human autoimmune arthritis: the unusual suspects. Nat Rev Rheumatol (2016) 0.78
Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes. J Autoimmun (2016) 0.78
Human Blood and Mucosal Regulatory T Cells Express Activation Markers and Inhibitory Receptors in Inflammatory Bowel Disease. PLoS One (2015) 0.78
β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice. Eur J Immunol (2016) 0.78
Promises and paradoxes of regulatory T cells in inflammatory bowel disease. World J Gastroenterol (2015) 0.77
Treating arthritis by immunomodulation: is there a role for regulatory T cells? Rheumatology (Oxford) (2010) 0.77
Targeted immune interventions for type 1 diabetes: not as easy as it looks! Curr Opin Endocrinol Diabetes Obes (2014) 0.77
Regulatory T Cells Control Th2-Dominant Murine Autoimmune Gastritis. J Immunol (2016) 0.76
Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes. Clin Exp Immunol (2013) 0.76
Analyses of regulatory CD4(+) CD25(+) FOXP3(+) T cells and observations from peripheral T cell subpopulation markers during the development of type 1 diabetes in children. Scand J Immunol (2016) 0.76
IL-1R1 is expressed on both Helios(+) and Helios(-) FoxP3(+) CD4(+) T cells in the rheumatic joint. Clin Exp Immunol (2015) 0.76
Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes. Stem Cells (2016) 0.76
Mechanisms of autoimmunity in the non-obese diabetic mouse: effector/regulatory cell equilibrium during peak inflammation. Immunology (2016) 0.76
Type I diabetes-associated tolerogenic properties of interleukin-2. Clin Dev Immunol (2011) 0.75
Gut immune deficits in LEW.1AR1-iddm rats partially overcome by feeding a diabetes-protective diet. Immunology (2015) 0.75
Immunological Basis for Rapid Progression of Diabetes in Older NOD Mouse Recipients Post BM-HSC Transplantation. PLoS One (2015) 0.75
Progress and challenges for treating Type 1 diabetes. J Autoimmun (2016) 0.75
Strategies for clinical trials in type 1 diabetes. J Autoimmun (2016) 0.75
Type-specific human papillomavirus detection in cervical smears in Romania. APMIS (2010) 0.75
Autoreactive T cells in type 1 diabetes. J Clin Invest (2017) 0.75
A novel and rapid method to quantify Treg mediated suppression of CD4 T cells. J Immunol Methods (2017) 0.75
APC-targeted proinsulin expression inactivates insulin-specific memory CD8(+) T cells in NOD mice. Immunol Cell Biol (2017) 0.75
IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Regulatory T Cell Suppression To Restrain Experimental Allergic Encephalomyelitis. J Immunol (2017) 0.75
On the Role IL-4/IL-13 Heteroreceptor Plays in Regulation of Type 1 Diabetes. J Immunol (2017) 0.75
Deranged regulatory T-cells and transforming growth factor-β1 levels in type 1 diabetes patients with associated autoimmune diseases. J Postgrad Med (2017) 0.75
Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet (2001) 14.15
X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet (2001) 10.92
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med (2007) 7.73
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest (2003) 6.42
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood (2006) 4.63
Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol (2004) 4.62
Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes (2005) 4.34
Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med (2005) 3.29
Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol (2007) 3.07
Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes (2005) 2.63
Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol (2003) 2.32
Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum (2008) 2.27
Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes (2005) 2.10
No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes (2007) 1.99
CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun (2005) 1.96
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol (2007) 1.92
Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A (2007) 1.81
Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J Immunol (2008) 1.42
Cutting edge: IL-12 induces CD4+CD25- T cell activation in the presence of T regulatory cells. J Immunol (2005) 1.32
Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. J Autoimmun (2008) 1.14
A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann N Y Acad Sci (2006) 1.11
Lymphocyte subset abnormalities, autoantibodies and their relationship with HLA DR types in children with type 1 (insulin-dependent) diabetes and their first degree relatives. Diabetologia (1994) 0.87
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest (2003) 6.42
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005) 5.04
Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol (2007) 3.52
Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood (2010) 3.52
Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. J Pediatr (2009) 3.48
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20
Predictors of insulin regimens and impact on outcomes in youth with type 1 diabetes: the SEARCH for Diabetes in Youth study. J Pediatr (2009) 2.74
De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc Natl Acad Sci U S A (2005) 2.57
Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. Pediatrics (2008) 2.56
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Dietary intake among youth with diabetes: the SEARCH for Diabetes in Youth Study. J Am Diet Assoc (2006) 2.35
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care (2006) 2.26
Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol (2009) 2.21
Etiological approach to characterization of diabetes type: the SEARCH for Diabetes in Youth Study. Diabetes Care (2011) 2.15
Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes (2009) 2.15
The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest (2011) 2.14
Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum (2011) 2.13
Lipid abnormalities are prevalent in youth with type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr (2006) 2.06
Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol (2007) 2.04
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. Diabetes Care (2013) 2.01
Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A (2012) 1.91
Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes (2009) 1.88
Change in blood-brain barrier permeability during pediatric diabetic ketoacidosis treatment. Pediatr Crit Care Med (2010) 1.76
CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. J Immunol (2011) 1.76
Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes (2009) 1.66
Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer (2007) 1.62
A Gender Assessment Team: experience with 250 patients over a period of 25 years. Genet Med (2007) 1.59
A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Rheum (2009) 1.59
Retracted Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest (2004) 1.58
Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. J Immunol (2006) 1.55
Change in mean transit time, apparent diffusion coefficient, and cerebral blood volume during pediatric diabetic ketoacidosis treatment. Pediatr Crit Care Med (2011) 1.53
Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum (2012) 1.52
Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics (2014) 1.49
Serum lipids and glucose control: the SEARCH for Diabetes in Youth study. Arch Pediatr Adolesc Med (2007) 1.49
GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes (2004) 1.41
FOXP3 and the regulation of Treg/Th17 differentiation. Microbes Infect (2009) 1.40
Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol (2011) 1.39
Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T cells. J Immunol (2007) 1.38
Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum (2008) 1.38
Transition from pediatric to adult care for youth diagnosed with type 1 diabetes in adolescence. Pediatrics (2013) 1.38
A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J Clin Invest (2013) 1.37
Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care (2009) 1.32
Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies. J Immunother (2004) 1.31
Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. J Autoimmun (2005) 1.28
CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta. J Immunol (2009) 1.28
Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes. J Clin Endocrinol Metab (2007) 1.28
HLA-DR1001 presents "altered-self" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis Rheum (2010) 1.27
HLA class II tetramers: tools for direct analysis of antigen-specific CD4+ T cells. Arthritis Rheum (2002) 1.24
Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care (2007) 1.22
Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol (2011) 1.22
Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives. Diabetes (2006) 1.21
Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells. J Leukoc Biol (2009) 1.20
T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog (2007) 1.19
CD4+ T cells from type 1 diabetic and healthy subjects exhibit different thresholds of activation to a naturally processed proinsulin epitope. J Autoimmun (2008) 1.15
Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. J Autoimmun (2008) 1.14
Use of a "fuzzy logic" controller in a closed-loop artificial pancreas. Diabetes Technol Ther (2013) 1.14
Autoimmunity and clinical course in children with type 1, type 2, and type 1.5 diabetes. J Autoimmun (2005) 1.14
The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes. Diabetes Care (2004) 1.13
Adherence to guidelines for youths with diabetes mellitus. Pediatrics (2011) 1.13
Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol (2014) 1.12
Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care (2011) 1.11
Autoimmunity to islet proteins in children diagnosed with new-onset diabetes. J Clin Endocrinol Metab (2004) 1.11
Early childhood gender differences in anterior and posterior cerebral blood flow velocity and autoregulation. Pediatrics (2007) 1.10
A haplotype-based analysis of the PTPN22 locus in type 1 diabetes. Diabetes (2006) 1.08
Hypertension despite dehydration during severe pediatric diabetic ketoacidosis. Pediatr Diabetes (2011) 1.07
Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes. Diabetes (2012) 1.07
Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA). Ann Rheum Dis (2012) 1.04
Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes (2007) 1.02
Permanent neonatal diabetes mellitus: prevalence and genetic diagnosis in the SEARCH for Diabetes in Youth Study. Pediatr Diabetes (2012) 1.02
Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes. Clin Immunol (2010) 1.02
Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects. Eur J Immunol (2009) 1.01
Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression? Pediatr Diabetes (2004) 1.00
Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. J Clin Endocrinol Metab (2006) 0.97
IL-2 therapy in type 1 diabetes: "Trials" and tribulations. Clin Immunol (2013) 0.97
Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes. Diabetes (2011) 0.96
Low-dose antigen promotes induction of FOXP3 in human CD4+ T cells. J Immunol (2011) 0.96
Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum (2013) 0.96
Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis. Arthritis Rheum (2013) 0.96